AzTrials
AzTrials

Muscular Dystrophy, DuchenneNCT01506518

Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular Dystrophy

An observational study of Muscular Dystrophy, Duchenne, run by University of North Carolina, Chapel Hill at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a pilot clinical trial to assess the ability of a new ultrasound-based imaging method, Double-Push Acoustic Radiation Force (DP ARF) ultrasound, to monitor the progression of Duchenne muscular dystrophy. Read more about this study

Who is it for?
Ages 5 to 13 years, men only
Conditions the study is for
Muscular Dystrophy, Duchenne
How many people
60 participants
Where
1 siteUnited States
Study dates
Jan 2012to 31 May 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 13 years
  • Men only
  • No healthy volunteers
  • Child

Study population: The study population will include patient volunteers with Duchenne muscular dystrophy (DMD). Thirty volunteers (boys with DMD, enrolling at ages 5 (n=10), 7 (n=10), or 9 (n=10)) having clinical diagnosis of DMD with clinical onset by age 5 will be considered for enrollment.

Who may be able to join

  • Clinical diagnosis of Duchenne muscular dystrophy with clinical onset by age 5
  • Ability to stand, alone or with assistance, at time of enrollment
  • Ability to communicate with pertinent staff
  • Ability to understand and comply with study requirements
  • Ability to give informed consent.

Who cannot join

  • Confirmed diagnosis of other muscle disease
  • Previous compartment syndrome
  • Previous injury to selected limbs
  • Previous vascular surgery to selected limbs
  • History of a compressive neuropathy (e.g., sciatic, femoral or tibial palsy in leg)
  • History of rhabdomyolysis

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The University of North Carolina at Chapel Hill Hospitals

    Chapel Hill, North Carolina, 27599

Other trials in United States

About this study

Official title: Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy

This is a pilot clinical trial to assess the ability of a new ultrasound-based imaging method, Double-Push Acoustic Radiation Force (DP ARF) ultrasound, to monitor the progression of Duchenne muscular dystrophy. The hypothesis being tested is that DP ARF ultrasound delineates changes in muscle composition and function in individual dystrophic muscles, from early through late stages of disease development, that correlate to time to loss of ambulation in patient volunteers.

Read the detailed description

Double Push Acoustic Radiation Force (DP ARF) imaging will be performed in 3 cohorts of up to 10 boys with DMD and in age-matched boys with no known neuromuscular disorders.

The first DMD cohort will enroll at age 5-6, the second at age 7-8, and the third at age 9-10. The rectus femoris (RF), cranial sartorius (CS), gastrocnemius (GAST), and lateral deltoid (DT) muscles will be targeted for their known phenotypic variation in response to dystrophin deficiency. The RF undergoes early necrosis and fatty deposition, the CS is thought to be relatively spared, and the GAST seems to undergo true hypertrophy. The DT, which undergoes hypertrophy like the GAST, will also be examined to determine if the impact of dystrophin deficiency varies between upper and lower limbs. All boys will be imaged 3 times annually for 4 years. In addition to DP ARF imaging every 4 mos, the boys will undergo standard quantitative muscle testing (QMT) and timed function tests (TFT) of time to standing, 6-minute walk, and 30-feet walk. Age at loss of ambulation will also be recorded for each boy. Boys with DMD generally loose ambulation by age 10, so we expect that the 20 boys in the 7-11 and 9-13 aged cohorts will lose ambulation over the course of this study. The 10 boys in the 5-9 aged cohort will likely not lose ambulation during the study. Because the primary objective of this clinical investigation is to evaluate the potential of DP ARF imaging as a relevant surrogate for monitoring disease progression and response to therapies, the focus of the study will be on correlating DP ARF results to change in functional degeneration and time to loss of ambulation.

There are two experimental components to this study beyond what is standard practice for DMD patients: 1) DP ARF ultrasound imaging of the rectus femoris (RF), cranial sartorius (CS), gastrocnemius (GAST), and lateral deltoid (DT) muscles and 2) standard quantitative muscle testing (QMT) and timed function tests (TFTs) of time to standing, 6-minute walk, and 30-feet walk repeated every four months (three times annually) throughout the four-year duration of the study.

This study will commence with DP ARF ultrasound imaging in the Clinical Neurophysiology Laboratory during the patient volunteer's first regularly scheduled research visit. Patient volunteers are expected to be outpatients. However, if a patient volunteer is an inpatient, DP ARF ultrasound imaging may be performed at the patient volunteer's hospital bedside. Immediately following DP ARF examination, the patient volunteer will undergo QMT and TFTs in the Physical Therapy Department. QMT and TFT will be conducted by trained physical therapists. DP ARF ultrasound imaging, QMT and TFT will be repeated as described above at each of the patient volunteers' twelve regularly scheduled research visits over the four-year study duration. Whenever possible, we will schedule research visits to coincide with other clinical visits to UNC. The patients' parents or caregivers will be compensated $50 per visit to defray the costs of travel to UNC, parking and lunch.

DP ARF will also be performed in 30 boys ages 5-14 with no known neuromuscular disorders. Imaging will be performed as described for the boys with DMD. The DP ARF results obtained in boys with no known neuromuscular disorders will be compared to those obtained in boys with neuromuscular disorders to serve as a control for changes in muscle mechanical property to occur with normal muscle growth and development.

DP ARF ultrasound is a noninvasive diagnostic imaging technology performed using commercially available clinical ultrasound imaging equipment - the Siemens Acuson Antares imaging system equipped for research purposes and VF10-5 or VF7-3 linear array transducers (Siemens Medical Solutions, USA Inc. Ultrasound Division). DP ARF imaging will be carried out by a professional sonographer, faculty and/or graduate student research assistants in the UNC-CH Joint Department of Biomedical Engineering. The sonographer will acquire DP ARF ultrasound data with matched B-Mode (for anatomical reference) in the right RF, CS, GAST, and DT muscles of patient volunteers. Patient volunteers will be asked to lie on an examination table in the Clinical Neurophysiology Clinic (outpatients) or to remain in their hospital beds (inpatients). The head of the exam table/bed may be raised to an approximate 45 degree angle to best visualize the muscles of interest with ultrasound imaging.

Once the patient volunteer is positioned, ultrasound gel will be applied to the patient volunteer's skin surface above the muscles of interest. The ultrasound imaging transducer will then be placed on top of the gel. Once the first muscle of interest is located, DP ARF ultrasound imaging will begin. We will orient the transducer to acquire ultrasound data transverse to the muscle fibers in the middle of the muscle length-wise, with three repeated acquisitions. We will then rotate our transducer 90 degrees to orient the imaging plane parallel to the muscle fibers. The previously imaged cross-section will be positioned in the approximate middle of the imaging field of view, with three repeated acquisitions. Muscle fiber orientation will be approximate, as surmised from anatomy. The DP ARF axial focal depth will be directed to the center of the muscle, approximately 20 - 30 mm.

The length of time for DP ARF data collection in each muscle is estimated to be less than 10 minutes. Once DP ARF imaging is completed on one muscle, DP ARF imaging will be performed on the other muscles of interest. Once all 4 muscles (RF, CS, GAST and DT) are imaged, the study procedure will be completed for the DP ARF imaging portion of the study.

For the second part of the study, beginning shortly (less than 4 hours) after DP ARF imaging is completed, the patient volunteer will undergo clinically standard quantitative muscle testing (QMT) of maximum voluntary isometric contraction (MVIC) in the right RF, CS, GAST and DT. The patient volunteer will also undergo clinically standard timed function tests (TFTs) of (1) time to rise from supine to standing, (2) distance walked in six minutes and (3) time to walk 30 feet.

Patient volunteers' participation will end once both study parts one (DP ARF ultrasound imaging) and two (QMT and TFT) are completed twelve times over 4 years. Therefore, there will be regularly scheduled follow-up visits required of the patient volunteers every four months. The patient volunteer is asked to assent and his parents are asked to permit their son to undergo (1) DP ARF ultrasound imaging of his right RF, CS, GAST and DT muscles, and (2) QMT and TFTs of time to standing, 6-minute walk, and 30-feet walk. No additional procedures or requirements are proposed. Every other aspect of the patient volunteers' care for DMD will be carried out in the normal standard of care as clinically indicated.

Keywords
Muscular Dystrophy, Duchenne, Ultrasound, Imaging, Acoustic Radiation Force, Double Push
Medical subject headings
Muscular Dystrophy, Duchenne

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01506518
Study groupRoleWhat they receive
Duchenne muscular dystrophy and age 5-6 yearsBoys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
Duchenne muscular dystrophy and age 7-8 yearsBoys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
Duchenne muscular dystrophy and age 9-10 yearsBoys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
No known neuromuscular disorders and age 5-14 yearsVolunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in DP ARF marginal peak displacement

    Marginal peak displacement (MPD) is a metric developed to qualitatively describe the degree of nonlinearity in the viscoelastic properties of tissue: MPD = (P2-D)/P1, where P1 and P2 are the first and second peak displacement achieved in tissue by the first and second ARF excitations, respectively, and d is the ARF-induced displacement remaining at the time of the second push.

    Measured: once every 4 months for 4 years for 12 total measures

Secondary outcomes (14)
  1. Rate of change in DP ARF marginal peak displacement

    rates of change in marginal peak displacement will be measured from time-point to time-point (every 4 months) and across multiple time points (spanning 8 months to 4 years).

    Measured: 4 months to 4 years

  2. Change in quantitative muscle testing score of maximum voluntary isometric contraction (MVIC)

    standard quantitative muscle testing of maximum voluntary isometric contraction (MVIC) in the rectus femoris, cranial sartorius, gastrocnemius, and lateral deltoid muscles of the right limbs.

    Measured: every 4 months for 4 years

  3. Change in time to rise from supine position to standing

    standard time to standing timed function test

    Measured: every 4 months for 4 years

  4. Change in distance walked in six minutes

    standard six-minute walk timed function test

    Measured: every 4 months for 4 years

  5. Change in time to walk 30 feet

    standard 30-feet walk timed function test

    Measured: every 4 months for 4 years

  6. Rate of change in maximum voluntary isometric contraction (MVIC)

    rate of change in maximum voluntary isometric contraction (MVIC) will be assessed from time-point to time-point (4 month separation between measures) and across time-points (8 months to 4 years time separation between measures).

    Measured: 4 months to 4 years

  7. Rate of change in time to rise from supine to standing position

    rate of change in time to standing timed function test score will be assessed from time-point to time-point (4 month separation between measures) and across time-points (8 months to 4 years time separation between measures).

    Measured: 4 months to 4 years

  8. Rate of change in distance walked in six minutes

    rate of change in six-minute walk timed function test score will be assessed from time-point to time-point (4 month separation between measures) and across time-points (8 months to 4 years time separation between measures).

    Measured: 4 months to 4 years

  9. Rate of change in time to walk 30 feet

    rate of change in 30-feet walk timed function test score will be assessed from time-point to time-point (4 month separation between measures) and across time-points (8 months to 4 years time separation between measures).

    Measured: 4 months to 4 years

  10. Age at loss of ambulation

    Loss of ambulation will be diagnosed by the patient volunteer's physician. The patient volunteer's age at the time loss of ambulation is first diagnosed will be recorded.

    Measured: 4 years

  11. Change in percent degenerative muscle composition

    Muscle boundaries will be hand-delineated using matched B-Mode image guidance in DP ARF marginal peak displacement parametric images. Within each 2D muscle image, percent degenerative area (Ad) will be calculated as T/N, where N is the total muscle area (number of pixels x area/pixel) and T is the muscle area in which marginal peak displacement values are within thresholds for necrosis, fat or fibrous tissue identification.

    Measured: every 4 months for 4 years

  12. Change in percent necrotic tissue area

    Muscle boundaries will be hand-delineated using matched B-Mode image guidance in DP ARF marginal peak displacement parametric images. Within each 2D muscle image, percent necrotic area (An) will be calculated as n/N, where N is the total muscle area (number of pixels x area/pixel) and n is the muscle area in which marginal peak displacement values are within thresholds for necrosis.

    Measured: every 4 months for 4 years

  13. Change in percent fat tissue area

    Muscle boundaries will be hand-delineated using matched B-Mode image guidance in DP ARF marginal peak displacement parametric images. Within each 2D muscle image, percent fatty deposition area (Af) will be calculated as f/N, where N is the total muscle area (number of pixels x area/pixel) and f is the muscle area in which marginal peak displacement values are within thresholds for fat tissue identification.

    Measured: every 4 months for 4 years

  14. Change in percent fibrotic tissue area

    Muscle boundaries will be hand-delineated using matched B-Mode image guidance in DP ARF marginal peak displacement parametric images. Within each 2D muscle image, percent degenerative area (Ac) will be calculated as c/N, where N is the total muscle area (number of pixels x area/pixel) and c is the muscle area in which marginal peak displacement values are within thresholds for fibrous tissue identification.

    Measured: every 4 months for 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jan 2012 (estimated)
  2. Study startJan 2012
  3. Primary completion31 May 2020
  4. Study completion31 May 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01506518
Sponsor's protocol ID
11-1509
Other IDs
1R01NS074057
Status last verified
May 2021
First submitted
22 Dec 2011
Last updated
2 Aug 2021
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Muscular Dystrophy, Duchenne, run by University of North Carolina, Chapel Hill at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in DP ARF marginal peak displacement (time frame: once every 4 months for 4 years for 12 total measures). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in